Unknown

Dataset Information

0

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.


ABSTRACT: Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance. We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance.HIV-infected pregnant Thai women with a CD4 cell count >250 cells/?L, most receiving zidovudine, were randomized at 28-38 weeks gestation to receive 1 of 3 intrapartum and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1 for 30 days. The incidence of NVP resistance mutations at day 10 or week 6 post partum in each arm was compared with that of a historical comparison group who received prenatal zidovudine and SD-NVP. NVP resistance was identified by consensus sequencing and a sensitive oligonucleotide ligation assay (OLA).At entry, the 169 participants had a median CD4 cell count of 456 cells/?L and an HIV load of 3.49 log(10) copies/mL. The incidence of mutations in each of the 3 P1032 arms was 0% by sequencing and 1.8%, 7.1%, and 5.3% by OLA in arms A, B, and C, respectively, compared with 13.4% by sequencing and 29.4% by OLA in the comparison group (P < .001 for each study arm vs comparison group). Grade 4 anemia developed in 1 woman.A 7-day tail of highly active combination therapy or 1 month of dual therapy after SD-NVP prevents most NVP resistance to minimal toxicity.The IMPAACT P1032 Clinical Trial is NCT00109590, and the PHPT-2 Clinical Trial is NCT00398684.

SUBMITTER: Van Dyke RB 

PROVIDER: S-EPMC3245730 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

Van Dyke Russell B RB   Ngo-Giang-Huong Nicole N   Shapiro David E DE   Frenkel Lisa L   Britto Paula P   Roongpisuthipong Anuvat A   Beck Ingrid A IA   Yuthavisuthi Praparb P   Prommas Sinart S   Puthanakit Thanyawee T   Achalapong Jullapong J   Chotivanich Nantasak N   Rasri Wirawan W   Cressey Tim R TR   Maupin Robert R   Mirochnick Mark M   Jourdain Gonzague G  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111205 2


<h4>Background</h4>Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance. We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance.<h4>Methods</h4>HIV-infec  ...[more]

Similar Datasets

| S-EPMC2922986 | biostudies-literature
| S-EPMC5054847 | biostudies-literature
| S-EPMC5853566 | biostudies-literature
| S-EPMC3588119 | biostudies-literature
| S-EPMC3719905 | biostudies-literature
| S-EPMC3590113 | biostudies-literature
| S-EPMC4871947 | biostudies-literature
| S-EPMC5850422 | biostudies-literature
| S-EPMC2994321 | biostudies-literature
| S-EPMC3594885 | biostudies-literature